(NYSE: HLN) Haleon's forecast annual revenue growth rate of -3.34% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 36.86%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 24.07%.
Haleon's revenue in 2026 is $14,588,311,688.On average, 20 Wall Street analysts forecast HLN's revenue for 2026 to be $108,241,678,050,804, with the lowest HLN revenue forecast at $100,556,845,923,330, and the highest HLN revenue forecast at $114,445,862,853,481. On average, 20 Wall Street analysts forecast HLN's revenue for 2027 to be $113,128,722,595,226, with the lowest HLN revenue forecast at $104,680,857,490,556, and the highest HLN revenue forecast at $120,141,359,004,694.
In 2028, HLN is forecast to generate $120,513,791,767,373 in revenue, with the lowest revenue forecast at $112,756,289,832,547 and the highest revenue forecast at $124,465,212,542,138.